CRSwNP market seen reaching $6.5 billion by 2030
The chronic rhinosinusitis with nasal polyps market is forecast to grow from $4.38 billion in 2025 to $6.5 billion by 2030, driven by rising respiratory disease cases, biologics adoption and more outpatient sinus procedures. North America led the market in 2025, while Asia-Pacific is expected to grow faster as healthcare access and awareness improve.
Why it matters: - Chronic rhinosinusitis with nasal polyps is a growing treatment market tied to broader respiratory disease trends. - Stronger demand for diagnostics, biologics and minimally invasive procedures could reshape care for patients with long-term sinus inflammation. - The forecast points to continued commercial momentum for companies developing ENT therapies and related diagnostic tools.
What happened: - The Business Research Company released its Chronic Rhinosinusitis Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 18, 2026. - The report says the CRSwNP market will rise from $4.38 billion in 2025 to $4.78 billion in 2026. - The report projects the market will reach $6.5 billion by 2030. - The report uses an 8.0% CAGR for the 2026-2030 forecast period.
The details: - Recent growth has been supported by more chronic sinus disorder cases and wider use of corticosteroid nasal sprays. - More frequent visits to ENT specialists and better access to advanced diagnostic imaging have also supported the market. - Rising awareness of inflammatory sinus diseases has added to demand. - The report defines chronic rhinosinusitis with nasal polyps as a long-lasting inflammatory disorder of the sinuses and nasal passages marked by benign swollen tissue masses. - Diagnosis typically includes symptom review, clinical examination, imaging, allergy testing and sometimes biopsy. - The report says future growth will be supported by more approvals of monoclonal antibody therapies. - More investment in biologics research for ENT conditions is also expected to support growth. - Outpatient sinus surgery, recurrence prevention efforts and demand for non-surgical treatment options are additional growth drivers. - Key trends in the forecast period include wider adoption of biologic therapies, minimally invasive surgery, long-term inflammation management, personalized treatment and better use of imaging with biomarker analysis. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report says Asia-Pacific and other emerging markets are likely to grow faster because of healthcare infrastructure investment and rising disease awareness. - The report also points to expanded strategic tools, including TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics and updated visuals. - A free sample is available here. - The full report is available here.
Between the lines: - The market outlook is being pulled by the same forces increasing respiratory disease prevalence worldwide, including pollution, smoking, climate change, infections, workplace exposures and allergies. - The report links rising asthma and COPD cases with more CRSwNP diagnoses and treatment demand. - A December 2023 National Center for Biotechnology Information report projects global COPD cases will approach 600 million by 2050. - The emphasis on biologics and non-surgical care suggests a shift toward longer-term disease control rather than repeated symptom management alone.
What's next: - The market’s next phase will likely be shaped by new monoclonal antibody approvals and broader biologics adoption. - Growth should also depend on how quickly outpatient surgical capacity, diagnostic imaging and biomarker-guided treatment expand. - Emerging markets may narrow the gap with North America if healthcare infrastructure spending and awareness keep rising.
The bottom line: - CRSwNP is moving from a niche ENT segment to a steadily expanding global market, with biologics and more precise diagnosis likely to define the next growth cycle.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
One World Daily Brief
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.